We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App

Automated Hematology Platform Offers High Throughput Analytical Performance

By LabMedica International staff writers
Posted on 05 Jan 2024
Print article
Image: The new HELO 2.0 modular high throughput automated hematology platform is CE-IVDR approved (Photo courtesy of HORIBA Medical)
Image: The new HELO 2.0 modular high throughput automated hematology platform is CE-IVDR approved (Photo courtesy of HORIBA Medical)

HORIBA Medical (Kyoto, Japan) has introduced HELO 2.0, a high throughput automated hematology platform with CE-IVDR approval, marking an evolution from its predecessor. This upgraded high-end hematology solution has been designed in response to customer feedback, aiming to fulfill the comprehensive needs of high throughput, fully automated hematology. Tailored for mid to large-scale laboratories, HELO 2.0 is a modular and highly flexible system, offering scalability and numerous configurations.

Available in three standard configurations, HELO 2.0 is suitable for both single-lab and multi-site operations, functioning as a standalone or integrated with a tracking system. The system’s track-based architecture allows continuous loading from multiple points, supplemented by a new automatic quality control transfer, enhancing sample workflow management for heightened efficiency. The system smartly distributes samples and quality control tubes to the designated analyzer and conducts blood smears based on reflex rules. Configurable with up to six analyzers and six slide preparation systems on a single track, it offers over 200 preloaded rules in the hematology expert validation station.

HELO 2.0 introduces innovative 8 Part Differential (DIFF) leukocyte results, providing a comprehensive analysis from a single blood sample. HORIBA's Yumizen H1500 and H2500 analyzers deliver complete blood count (CBC) and DIFF results, along with a total immaturity measurement for leukocyte count, ideally suited for oncology pathologies. Additional enhancements include a Nucleated Red Blood Cell count free from platelet aggregate interference and three new large platelet parameters devoid of fluorescence. Eleven additional parameters have been incorporated across its three quality controls. Designed to be environmentally friendly, HELO 2.0 has received the 2023 Medical Device Network Excellence Award in the Environmental category, highlighting its eco-friendly approach. Notably, the Yumizen H2500 analyzer requires only six reagents compared to the typical 8-15, significantly reducing reagent usage, waste, toxicity, and packaging.

“One of the biggest challenges for laboratories is to obtain accurate results for an ever-increasing number of samples within shorter turnaround times,” said Arnaud Pradel, General Manager, HORIBA Medical. “So, listening to our customers’ feedback, we have again applied our hematology expertise and heritage for innovation to further enhance our HELO automated hematology platform. In the HELO 2.0 we offer an even more flexible and efficient system to reduce slide review rate that provides an optimum solution to the ever-evolving needs of many different laboratories.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article


Molecular Diagnostics

view channel
Image: Prostate cancer cell image taken using a scanning electron microscope (Photo courtesy of LRI EM Unit)

New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it.... Read more


view channel
Image: The photoacoustic spectral response sensing instrument is based on low-cost laser diodes (Photo courtesy of Khan et al., doi 10.1117/1.JBO.29.1.017002)

Compact Photoacoustic Sensing Instrument Enhances Biomedical Tissue Diagnosis

The pursuit of precise and efficient diagnostic methods is a top priority in the constantly evolving field of biomedical sciences. A promising development in this area is the photoacoustic (PA) technique.... Read more


view channel
Image: The companies will develop genetic testing systems based on capillary electrophoresis sequencers (Photo courtesy of 123RF)

Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems

Sysmex Corporation (Kobe, Japan) and Hitachi High-Tech Corporation (Tokyo, Japan) have entered into a collaboration for the development of genetic testing systems using capillary electrophoresis sequencers... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.